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Abstract
Background: Non adherent bone marrow derived cells (NA-BMCs) have recently been described to give rise to multiple
mesenchymal phenotypes and have an impact in tissue regeneration. Therefore, the effects of murine bone marrow derived
NA-BMCs were investigated with regard to engraftment capacities in allogeneic and syngeneic stem cell transplantation
using transgenic, human CD4+, murine CD42/2, HLA-DR3+ mice.
Methodology/Principal Findings: Bone marrow cells were harvested from C57Bl/6 and Balb/c wild-type mice, expanded to
NA-BMCs for 4 days and characterized by flow cytometry before transplantation in lethally irradiated recipient mice.
Chimerism was detected using flow cytometry for MHC-I (H-2D[b], H-2K[d]), mu/huCD4, and huHLA-DR3). Culturing of bone
marrow cells in a dexamethasone containing DMEM medium induced expansion of non adherent cells expressing CD11b,
CD45, and CD90. Analysis of the CD45+ showed depletion of CD4+, CD8+, CD19+, and CD117+ cells. Expanded syngeneic and
allogeneic NA-BMCs were transplanted into triple transgenic mice. Syngeneic NA-BMCs protected 83% of mice from death
(n = 8, CD4+ donor chimerism of 5.862.4% [day 40], P,.001). Allogeneic NA-BMCs preserved 62.5% (n = 8) of mice from
death without detectable hematopoietic donor chimerism. Transplantation of syngeneic bone marrow cells preserved
100%, transplantation of allogeneic bone marrow cells 33% of mice from death.
Conclusions/Significance: NA-BMCs triggered endogenous hematopoiesis and induced faster recovery compared to bone
marrow controls. These findings may be of relevance in the refinement of strategies in the treatment of hematological
malignancies.
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Introduction
Today, allogeneic hematopoietic stem cell transplantation
(HSCT) is the only curative treatment for many patients with
hematological malignancies [1].
Bone marrow [2], peripheral mobilized stem cells [3] and
umbilical cord blood [4] are the common sources for HSCT.
Despite the use of highly sophisticated therapeutic approaches,
HSCT is still associated with a considerable mortality caused by a
number of complications such as graft versus host disease (GVHD)
[5], infectious diseases [6], veno-occlusive disease [7], donor graft
rejection [8], and relapses of the underlying diseases [9].
Therefore, the investigation of alternative therapeutic approaches
including the use of new stem cell sources and the optimization of
treatment strategies are still in need.
Thus, mesenchymal stem cells (MSCs) are used in clinical
hematopoietic stem cell transplantation to support hematopoi-
esis. Previous studies indicate that co-transplantation of
mesenchymal stem cells results in faster engraftment of
hematopoietic cells [10,11]. MSCs as well as MSC derived
cells provide growth factors essential for hematopoiesis [12–14].
These cells are a very promising stem cell type for transplan-
tation because MSCs are easy available and modest regarding
their requirements for in vitro expansion. Furthermore, MSCs
show no spontaneous transformations [15] and are character-
ized as highly adherent fibroblastic cells (counted as CFU-f)
[16,17], which attach within 24 hours [16]. It has also been
shown that there are other cells derived from CFU-f, which are
able to transform into mesenchymal cells, but also into cells of
other lineages [18].
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Recent studies have investigated whether non adherent bone
marrow cells derived from CFU-f (NA-BMCs) have a therapeutic
impact in hematopoietic stem cell transplantation. In contrast to
the long expansion time of MSCs that can be a major handicap to
cell-based therapies [19], NA-BMCs investigated in this study have
a short cultivation time of only 4 days. It has been shown that
MSC-like cells within NA-BMCs keep their mesenchymal
potential [20] and form CFU-fs in vitro [21,22], skeletal muscle
[23] and bone [24] after in vivo transplantation. NA-BMCs
include all cells after cultivation of bone marrow cells. Other
results published in the literature indicate controversy regarding
the exact identity of cells investigated [20]. These cells could
differentiate into hematopoietic as well as stromal cell lineages and
were also a major source for adult stem cells [18].
In this work we investigated the effects of allogeneic and
syngeneic non adherent bone marrow cells on the reconstitution of
hematopoiesis in lethally irradiated CD42/2 C57Bl/6 mice
transgenic for human CD4 and HLA-DR3 (triple transgenic mice,
TTG) [25,26]. In this setting the presence of human or murine
CD4 after transplantation can be used as a marker for chimerism
even in a syngeneic setting. Engraftment of allogeneic and
syngeneic stem cells was monitored by murine CD4+ cells.
Endogenous recovery will lead to expression of human CD4+
and/or HLA-DR3+ cells.
Here we demonstrate that transplantation of syngeneic NA-
BMCs protected 83% of irradiated mice from death. Transplan-
tation of allogeneic NA-BMCs preserved 62.5% of mice from
death. Interestingly, in contrast to the syngeneic transplantation
procedure, in allogeneic NA-BMCs transplantation no hemato-
poietic donor chimerism was found, demonstrating that allogeneic
NA-BMCs did not engraft but supported endogenous stem cell
recovery. Compared to bone marrow controls, hematopoietic
regeneration in both NA-BMCs-transplanted groups was faster.
These findings might be of relevance in the refinement of strategies
in the treatment of hematological malignancies.
Results
1. Determination of lethal irradiation toxicity in triple
transgenic mice
To determine the lethal irradiation dose in triple transgenic
mice for engraftment of NA-BMCs and bone marrow cells groups
of four triple transgenic mice were irradiated with X-rays ranging
from 0 to 12 Gy followed by analysis of weight, survival, and
recovery of peripheral red blood cells. Irradiation of mice with
doses $8 Gy led to death of all mice within 19 days, while mice
irradiated with doses ,8 Gy survived (Figure S1). Irradiated mice
served as transplantation controls and received the same injection
volume without cells. For further transplantation experiments all
mice were irradiated with 8 Gy.
2. Characterization of bone marrow cells and NA-BMCs
For characterization of cell subsets, NA-BMCs and bone
marrow cells were analyzed by flow cytometry for CD11b,
CD117, CD4, CD8, CD19, CD31, CD90, CD117, and MHC-II
expression in the CD45+ cell fraction.
Compared to bone marrow cells, NA-BMCs derived from
Balb/c and C57Bl/6 showed a significant increase of CD11b+ and
CD90+ and a significant decrease of cells expressing CD117+,
CD117+/CD90low, T-cell and B-cell markers (CD4+, CD8+,
CD19+) (Figure 1, shown for C57Bl/6 mice and Figure S2). In
C57Bl/6 derived bone marrow the proportion of CD45high was
80.5%60.5% and in Balb/c derived bone marrow 87.4%62.6%,
respectively. After culturing, the proportion of CD45high was
41%67% in C57Bl/6 mice and 52.7%614%in Balb/c mice,
respectively.
3. Transplantation of allogeneic and syngeneic NA-BMCs
For investigation if allogeneic and syngeneic NA-BMCs will
engraft after lethal irradiation, triple transgenic mice received
either NA-BMCs grafts containing 16105 to 26106 NA-BMCs
from Balb/c wild-type or C57Bl/6 mice. These experiments were
compared to allogeneic and syngeneic bone marrow transplanta-
tion using 26106 cells.
In the control experiments, transplantation of 26106 syngeneic
bone marrow cells preserved 100% of mice from death (Figure 2A).
The survival rate of mice that had received 26106 syngeneic NA-
BMCs was 83%, in mice that had received 16106 it was 66% and
0% in mice receiving 16105.
Transplantation of 26106 allogeneic bone marrow cells
preserved 33% of mice from death (Figure 2B). Also for ethical
reasons we used a system to characterize the clinical status (weight,
mobility, texture of the fur, attitude, skin appearance) as published
by others [27] for characterization of animals after transplantation.
In dying animals, we observed loss of weight, reduced mobility,
shaggy fur, and kyphotic attitude. WBC count remained low and
time points of death were comparable with the irradiation control
groups. Surviving animals showed no signs of GvHD after
allogeneic bone marrow transplantation.
In mice that had received 26106 allogeneic NA-BMCs the
survival of mice was 62.5% and 0% in animals that had received
16106 and 16105, respectively. Statistical comparisons are given
in table 1.
For evaluation of the transplantation procedure related toxicity
and engraftment, weekly blood counts in all irradiated mice were
performed and concentration of white blood cell count (WBC) was
performed (Figure 2C+D). The recovery of WBC after transplan-
tation of 26106 syngeneic NA-BMCs was significantly earlier at
day 35 and 50 compared to transplantation of 26106 syngeneic
BM cells (day 35 *P= .023, day 50 **P= .006). After transplan-
tation of 26106 allogeneic NA-BMCs, the reconstitution of WBC
was also earlier compared to transplantation of 26106 allogeneic
BM cells and achieved significant difference at day 28 (day 28
**P= .019).
We also determined the distribution of lymphocytes, granulo-
cytes, and monocytes once a week. The recovery of hematopoiesis
after allogeneic bone marrow transplantation was delayed for all
leukocyte subsets and the lymphocyte subset did not reach the
initial levels. After transplantation of 26106 allogeneic NA-BMCs,
granulocytes and monocytes recovered earlier than lymphocytes.
The faster WBC recovery after allogeneic NA-BMCs transplan-
tation compared with allogeneic bone marrow transplantation was
due to increased myeloid and lymphoid content (Figure 3A).
After syngeneic NA-BMCs and bone marrow transplantation,
the reconstitution of hematopoiesis was similar and granulocytes
and monocytes recovered earlier than lymphocytes (Figure 3B).
4. Analysis of hematopoietic chimerism after
transplantation of allogeneic and syngeneic NA-BMCs
Human and murine CD4 as well as HLA-DR3 molecules were
used for detection of chimerism by flow cytometry. On day 40
after transplantation of allogeneic NA-BMCs the MHC-I
expression of donor Balb/c (H-2K[d]) remained low (3.162.6%)
while the recipient MHC-I molecules of C57Bl/6(H-2D[b]) were
highly expressed (94.365.4%) (Figure 4A). Donor Balb/c (H-
2K[d]) MHC-I expression remained low after transplantation until
the end of the experiment (Table 2). Murine CD4 was not
detectable (0.2860.13%) (Figure 5A+B). Human CD4 molecules
Therapeutic Use of NA-BMCs
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were stable expressed from day 21 until the end of the experiment
whereas human HLA-DR3 molecules were not expressed until
day 40 (Figure 6A+B) indicating that the recurrence of host HLA-
DR3 presenting cells was later than host CD4 T cells.
After transplantation of syngeneic C57Bl/6 NA-BMCs, recur-
rence of MHC-I from C57Bl/6 (H-2D[b]) molecule was
98.860.8% on day 40 (Figure 4B). Recipient/Donor MHC-I
molecules of C57Bl/6 (H-2D[b]) were stable expressed after
transplantation (Table 3). Balb/c (H-2K[d]) MHC-I expression
remained low and was 1.0960.40 at day 40 after transplantation.
For murine donor CD4, a chimerism of 5.862.4% on day 40 was
observed (Figure 5A, P,.001) indicating the engraftment of
transplanted syngeneic cells. Murine CD4 was detectable for the
first time on day 33 and persists until the end of the experiment
(Figure 5B). Human CD4 molecules were stable expressed from
day 21 until the end of the experiment whereas human HLA-DR3
molecules were not expressed until day 40 (Figure 6A+B). These
data indicated the parallel recovery of recipient and donor cells.
The recurrence of donor CD4 T cells and host HLA-DR3
presenting cells was later than host CD4 T cells.
Transplantation of 26106 allogeneic and syngeneic bone
marrow cells induced the reconstitution of a complete host
hematopoiesis (Figure 4C). Flow cytometric analysis showed very
few non-CD3+ lymphocytes and a high proportion of CD3+
lymphocytes in surviving mice after allogeneic compared to
syngeneic bone marrow transplantation. Co-transplantation of
Figure 1. Comparative flow cytometric analysis of bone marrow and NA-BMCs (shown for C57Bl/6). Cells were gated for CD45
expression and co-expression of CD117, CD90 and CD11b for bone marrow cells and NA-BMCs.
doi:10.1371/journal.pone.0006157.g001
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Figure 2. Survival analysis (A+B) and recovery of white blood cell count (WBC, C+D) after irradiation and transplantation. Transgenic
mice (C57Bl/6) received either syngeneic or allogeneic NA-BMCs (16105 to 26106 cells) or syngeneic and allogeneic bone marrow (26106 cells).
Recovery of WBC after lethal irradiation and transplantation of 26106 syngeneic NA-BMCs or 26106 syngeneic bone marrow cells (C) and 26106 of
allogeneic NA-BMCs compared to transplantation of 26106 allogeneic bone marrow cells (D).
doi:10.1371/journal.pone.0006157.g002
Table 1. P values after syngeneic and allogeneic transplantation.
pairs P values
Syngeneic NA-BMCs allogeneic NA-BMCs
26106 NA-BMCs vs. 16105 NA-BMCs **P = .002 P = .057 NS
26106 BM cells vs. 16105 NA-BMCs **P = .003 P = .094 NS
16106 naSCs vs. 16105 NA-BMCs **P = .007 P = .402 NS
26106 NA-BMCs vs. 26106 BM cells P = .005 NS P= .5 NS
16106 NA-BMCs s vs. 26106 BM cells P = 0.261 NS P= .332 NS
and 26106 NA-BMCs s vs. 16106 NA-BMCs P = 0.53 NS *P = .041
doi:10.1371/journal.pone.0006157.t001
Therapeutic Use of NA-BMCs
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46106 allogeneic murine spleen cells and 16107 allogeneic bone
marrow cells induced engraftment of donor cells in surviving mice
in this model (Figure 4D).
Discussion
In this study, we investigated the engraftment kinetics and
development of chimerism of allogeneic and syngeneic murine non
adherent bone marrow cells (NA-BMCs) transplanted into triple
transgenic mice.
The TTG transplantation model allows the analysis of
chimerism and the discrimination between donor and host
hematopoiesis in syngeneic and allogeneic transplantation settings
by the expression of murine or human CD4 and HLA. However,
for the detection of non-lymphoid cell lineages other mouse strain
combinations will be preferable. For the differentiation of donor
and host cells also other congenic mouse strain combinations were
used [28]. Using triple transgenic mice, we are able to simulate the
functional interaction between human CD4 and human MHC-II
molecules. Therefore, the TTG mice will be used for development
Figure 3. Recovery analysis of lymphocytes, monocytes, and granulocytes after irradiation and transplantation of 26106 NA-BMCs
and 26106 bone marrow cells. Data are shown for (A) allogeneic transplantation and (B) syngeneic transplantation.
doi:10.1371/journal.pone.0006157.g003
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of GvHD and host versus graft (HvG) treatment strategies as well
as for tolerance induction using monoclonal antibodies.
We hypothesized that transplantation of NA-BMCs and bone
marrow of C57Bl/6 wild-type mice represents a syngeneic
transplantation setting in contrast to bone marrow or NA-BMCs
derived from wild type Balb/c representing an allogeneic
transplantation setting. However, because multiple mice strains
were used for developing the TTG mice, little MHC minor
differences can not be totally excluded (for Balb/c MHC-I, H-
2K[d] ,2% by flow cytometry).
In order to characterize NA-BMC grafts whether they have an
impact on HSCT, NA-BMCs were cultured from bone marrow
cells by depletion of adherent cells over a period of four days. Flow
cytometric analysis showed that CD45 positive NA-BMCs were
positive for CD11b, CD90 and had low amounts of CD4+, CD8+,
CD19+, and CD117+ cells. The amount of hematopoietic stem
cells (CD117+/CD90low) was low. In contrast, bone marrow cells
expressed high levels of CD4+, CD8+, CD19+, and CD117+ cells
and low levels of CD11b+ and CD90+ cells.
The proportion of CD45high to CD45low cells was different
before and after cultivation of bone marrow cells. During
cultivation, the CD45low fraction increased and the CD45high
fraction decreased indicating that NA-BMCs contained more
progenitors and less differentiated hematopoietic stem cell
compared to regular bone marrow cells.
However, there are no direct data demonstrating a true stem
cell activity. The term NA-BMCs is not claiming one single cell
Figure 4. Flow cytometric analysis of MHC-I and CD3 on day -2 before and day 40 after transplantation. MHC-I (H-2D[b], H-2D[d]) and
CD3 levels from peripheral blood (gated for lymphocytes) on day 40 after allogeneic NA-BMCs (A), syngeneic NA-BMCs (B) or allogeneic bone marrow
(C) transplantation. In co-transplanted animals with allogeneic bone marrow and murine splenocytes we additionally analyze the murine CD4/H-2K[d]
and CD8/H-2K[d] expression on bone marrow cells to show donor engraftment.
doi:10.1371/journal.pone.0006157.g004
Table 2. Analysis of donor Balb/c (H-2K[d]) chimerism after
transplantation of 26106 allogeneic NA-BMCs.
day Donor Balb/c (H-2K[d]) (% of CD45
+)
26106 allogeneic NA-BMCs
0 1.160.4
21 0.160.1
33 0.9760.57
40 3.162.62
50 0.5760.31
doi:10.1371/journal.pone.0006157.t002
Therapeutic Use of NA-BMCs
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population. Culturing bone marrow cells over a period of 4 days
resulted in a mixed cell population, which probably also contains
few HSCs and MSCs. Currently, there are no data that clearly
identify a single cell type with simultaneous mesenchymal and
hematopoietic capacity. Clonal analyses of the mixed cell culture
must be done in future to verify a transplantation effect of a
defined cell population.
Next, we investigated the impact and the kinetics of engraftment
of syngeneic or allogeneic NA-BMCs on the survival of irradiated
TTG mice. Transplantation of syngeneic NA-BMCs preserved up
to 83 % of mice in a dose dependent manner. Transplantation of
syngeneic bone marrow cells induced hematopoietic recovery of
100% of mice.
Transplantation of 26106 allogeneic NA-BMCs preserved up to
62.5 % of mice from death. Lower amounts of NA-BMCs did not
lead to recovery of hematopoiesis. Transplantation of 26106
allogeneic bone marrow cells preserved 33% of mice from death,
which might indicate that in the TTG model higher numbers of
cells with hematopoietic capacity are needed because the
additional administration of allogeneic splenocytes induced
allogeneic chimerism in surviving mice. Because WBC count
remains low and time points of death were comparable with the
irradiation control groups in dying animals after allogeneic bone
marrow transplantation, we deduced that the cause of death was
hematopoietic failure. Surviving animals showed no signs of
GvHD after bone marrow transplantation. There are no data
available using TTG mice in a bone marrow transplantation
setting. The influence of transgenic molecules with regard to
mechanisms of engraftment, GvHD, and HvG are still unknown
(e.g. distribution and selection of regulatory T cells in transgenic
mice). After allogeneic bone marrow transplantation, flow
cytometric analysis showed very few non-CD3+ lymphocytes and
a high proportion of CD3+ lymphocytes in surviving mice.
Recovery of hematopoiesis was significantly decelerated compared
to syngeneic bone marrow or allogeneic/syngeneic NA-BMCs
transplantation and did not reach the initial levels. We hypothesize
that the immune systems of the surviving recipient mice
transplanted with 26106 allogeneic bone marrow cells are
triggered by the graft and endogenous CD3+ lymphocytes are
activated. This might lead to a shift in CD3+ and non CD3+
lymphocytes after allogeneic bone marrow transplantation com-
pared to syngeneic bone marrow transplantation.
Interestingly, hematopoietic recovery in mice transplanted with
syngeneic or allogeneic NA-BMCs was faster indicated by higher
peripheral white blood counts compared to mice that had received
syngeneic or allogeneic bone marrow cells.
Figure 5. Flow cytometry analysis of murine CD3/CD4 (gated for lymphocytes) from peripheral blood on day -2 before and day 40
after transplantation. Data are shown for transplantation of allogeneic and syngeneic NA-BMCs (A). CD4 molecules were stable expressed after
syngeneic transplantation, not after allogeneic transplantation of NA-BMCs (B).
doi:10.1371/journal.pone.0006157.g005
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We also determined the distribution of lymphocytes, granulo-
cytes, and monocytes once a week. After syngeneic and allogeneic
NA-BMCs transplantation, the reconstitution of granulocytes and
monocytes was earlier than lymphocytes. The recovery of
hematopoiesis after allogeneic bone marrow transplantation was
delayed for all subsets and did not reach the initial levels.
Therefore, the faster WBC recovery after allogeneic NA-BMCs
transplantation compared with allogeneic bone marrow trans-
plantation was due to increased myeloid and lymphoid content.
For analysis of hematopoietic chimerism we examined the
presence of murine and human CD4 molecules after transplan-
tation of NA-BMCs.
After transplantation of allogeneic and syngeneic NA-BMCs,
human CD4+ cells that represent the endogenous hematopoiesis
were stable expressed from day 21 until the end of the experiment
whereas human HLA-DR3+ cells on host antigen presenting cells
were not detected until day 40. Syngeneic NA-BMCs transplan-
tation led to a recovery of murine CD4+ cells not until day 33 after
transplantation representing the donor hematopoiesis. The human
CD4 molecule is specific for host T cell subsets in this model
indicating that recovery of host CD4+ T lymphocytes is earlier
than recovery of donor CD4+ T cells and host HLA-DR3+ antigen
presenting cells. Therefore, the recovery of endogenous lymphoid
cells is earlier than recovery of endogenous antigen presenting cells
in this model.
Interestingly, after transplantation of allogeneic NA-BMCs we
could detect only human CD4 and HLA molecules as a marker of
autologous recovery. By contrast, in the syngeneic setting,
chimerism analysis of murine CD4 indicated engraftment of the
Figure 6. Flow cytometry analysis of human CD4/HLA-DR3 (gated for lymphocytes) from peripheral blood on day -2 before and day
40 after transplantation. Data are shown for transplantation of allogeneic and syngeneic NA-BMCs (A). Human CD4 molecules were stable
expressed from day 21 after transplantation until the end of the experiment whereas human HLA-DR3 molecules were not expressed until day 40 (B).
doi:10.1371/journal.pone.0006157.g006
Table 3. Analysis of donor/recipient C57Bl/6 (H-2D[b])
chimerism after transplantation of 26106 syngeneic NA-BMCs.
day Donor/Recipient C57Bl/6 (H-2D[b]) (% of CD45
+)
26106 syngeneic NA-BMCs
0 99.1960.17
21 74.80612.45
33 97.0262.56
40 98.5560.99
50 98.6260.48
doi:10.1371/journal.pone.0006157.t003
Therapeutic Use of NA-BMCs
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murine syngeneic donor cells. These data indicate that allogeneic
NA-BMCs do not engraft but facilitate autologeous recovery of
hematopoiesis.
However, up to now there is no exact mechanism explaining the
regulatory effects of allogeneic NA-BMCs. Although, the irradi-
ation dosage is equivalent to the current protocols used in other
transplantation settings [29], this minimal dosage probably permits
survival of significant numbers of endogenous host stem cells that
can be activated after transplantation of allogeneic NA-BMCs. It is
possible, that the therapeutic benefit of allogeneic NA-BMCs on
improved survival can only be observed using this radiation
setting. Therefore, transplantation of NA-BMCs after irradiation
with higher dosages should be investigated. As already mentioned
above, transplantation of autologeous or allogeneic pluripotent
NA-BMCs will reconstitute both the hematopoietic cells and the
BM microenvironment [18]. Because NA-BMCs are not a
homogenous cell population, remaining MSCs are also able to
support host hematopoiesis, e.g. by induction of G-CSF produc-
tion. The application of G-CSF can also have a supporting effect
after lethal irradiation. The effects of recombinant canine
granulocyte colony-stimulating factor (rcG-CSF) and recombinant
canine stem cell factor (rcSCF) on the circulation of hematopoietic
progenitor and stem cells were studied in a canine model [30]. In
this study, control animals transplanted with 16108 PBMC/kg
collected without pre-treatment died with marrow aplasia after
irradiation as did animals treated with only low-dose SCF before
cell collection. In contrast, all animals given PBMC collected after
G-CSF, high-dose SCF, or a combination of G-CSF plus low-dose
SCF recovered granulocyte function. It has been shown that use of
supportive care and G-CSF enhanced recovery of myelopoiesis
and survival after lethal doses of irradiation [31] although the
authors postulate that administration of G-CSF should be as soon
as possible after irradiation. Other investigators have demonstrat-
ed that administration of HGFs (GM-CSF, IL-3 and SCF) in
lethally irradiated C3H mice did not convey any in vivo
radioprotection [32].
Other groups showed that stromal cells derived from hemato-
poietic progenitors (probably present in NA-BMCs) support
hematopoiesis [33]. There are several studies in animal models
demonstrating that stromal cells not only seed the bone marrow
but also enhance hematopoietic recovery [34,35]. The differen-
tiation of single BM derived cell types along both hematopoietic
and mesenchymal lineages is possible and controversially discussed
[20].
Our findings show that NA-BMCs engraft in a syngeneic
transplantation setting and lead to survival of at least fifty days.
Therefore, these cells have supportive function for hematopoiesis.
In the allogeneic transplantation setting NA-BMCs support
autologous recovery indicated by detection of host chimerism.
Syngeneic and allogeneic NA-BMCs induce faster recovery of
hematopoiesis and reduce transplantation related toxicity. To our
knowledge this is the first report describing such effects of NA-
BMCs in mice. These findings may have an impact on clinical
transplantation settings. NA-BMCs will probably have an impact
in treatment of critically ill hematological patients after allogeneic
transplantation. Furthermore, NA-BMCs might be useful in cases
of severe irradiation exposure or toxic organ damage. An
important finding is the higher frequency of relapses in leukemia
patients after allogeneic bone marrow transplantation compared
to peripheral mobilized blood stem cell grafts [3]. NA-BMCs can
not only trigger stem cells of the graft (as shown for murine CD4)
but also trigger residual hematopoietic stem cells of the host (as
shown for human CD4 and HLA-DR3). Therefore, NA-BMCs
may be able to trigger remaining tumor cells that probably reduce
the therapeutic applicability in leukemic patients. This could be
caused by higher frequencies of progenitors in bone marrow
derived NA-BMCs compared to peripheral blood. However, the
effect of NA-BMCs regarding tumor recurrence and graft versus
tumor effect must be investigated in appropriate tumor models.
Materials and Methods
Ethics Statement
All mice were housed, treated or handled in accordance with
the guidelines of the University of Leipzig Animal Care
Committee and the Regional Board of Animal Care for Leipzig
(animal experiment registration number 24/06).
Animals
C57Bl/6 CD4k/o mice transgenic for human CD4 and HLA-
DR (TTG mice) were bred at the Animal Facility at the University
of Leipzig. The mice strain was maintained under standardized
conditions. These mice have a stable C57Bl/6 background, in
which the murine CD4 molecule is knocked out and replaced by
human CD4. The CD4 transgene includes its own promoter
ligated to a murine CD4 enhancer element thus leading to T cell
subset-specific expression. CD8+ cells are not affected in TTG
mice Furthermore, these mice express the HLA-DR3 molecule in
addition to the murine MHC II complex. The TTG mice have
complete functional murine immune system which is modified
with regard to CD4 and HLA-DR [36]. The mice were fed ad
libitum. As donors, C57Bl/6 and Balb/c mice were purchased
from Charles River (Sulzfeld, Germany; http://jaxmice.jax.org).
Irradiation protocol
For irradiation of mice the X-Ray apparatus (D3225,
Orthovoltage, Gulmay Medical, Camberley, UK) was adjusted
for animal irradiation. 4 animals were irradiated in parallel in a
plexiglass container (divided in five spaces per 0.5 cm64.0 cm).
For determination of the lethal irradiation dose, 16 mice
underwent single total body irradiation with irradiation doses
from 3 Gy to 12 Gy (200 kV, dose rate 1,14 Gy/min), 4 mice
were used as non irradiated control mice.
Culture of non adherent bone marrow cells (NA-BMCs)
derived from murine bone marrow and preparation of
bone marrow and splenocytes
Bone marrow cells (BMCs) were obtained from tibiae and
femura from C57Bl/6 and Balb/c wild-type mice according to the
method of Dobson et al [37], and expansion was started at a
concentration of 26106/55 cm2 Petri dishes in 10 ml Dulbecco’s
modified Eagle’s minimal essential medium (DMEM, Perbio,
Bonn, Germany) modified as described by others [20]. The
medium was supplemented with 10% fetal calf serum (FCS,
Invitrogen, Karlsruhe, Germany) and dexamethasone (1028 M).
Murine splenocytes were prepared as described elsewhere [38].
Flow cytometry
Characterization of murine NA-BMCs and bone marrow
cells. For cytometric analysis, 26105 cells were incubated with
2.5 ml of conjugated monoclonal antibodies (CD3-FITC, CD8-
APC [both Beckman Coulter, Krefeld, Germany]; MHC-II-PE,
CD4-PECy7, CD45-PerCP, CD19-APCCy7, CD31-FITC,
CD90-PE, CD117-APCCy7, CD11b-APCCy7 [BD Biosciences,
Heidelberg, Germany]). A 25 minutes incubation was followed by
two washing steps in PBS/1% FBS (1250 rpm, 5 minutes, RT).
Finally the pellet was resuspended with 200 ml of PBS/3%
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formaldehyde (Merck, Darmstadt, Germany). Data were acquired
on a BD FACSCantoIITM Flow Cytometer and analysed using the
BD FACSDIVATM software (both BD Biosciences, Heidelberg,
Germany).
Flow cytometry and hematology of TTGmice. Before and
after transplantation procedure, recipient mice were analyzed by
flow cytometry. At particular time points, blood (150 ml) was taken
from the retro orbital vein of each mouse under ether anesthesia.
Blood was collected through heparinized capillaries (Greiner
Biochemica, Flacht, Germany). Hemoglobin concentration was
determined using an Animal Blood Counter (SCIL, Viernheim,
Germany), which had been calibrated for mouse blood within 2
hours after blood taking.
For cytometric analysis 100 ml of blood cells were incubated
with 2.5 ml of conjugated monoclonal antibodies according to
samples (murine CD4-PE, MHC-I (H-2D[b])-PE, MHC-I (H-
2K[d])-PE [BD Biosciences, Heidelberg, Germany]; murine CD3-
FITC, murine CD8- APC, human CD4-PE [Beckman Coulter,
Krefeld, Germany]; human HLA-DR3-FITC [Immunotools,
Friesoythe, Germany]). 25 minutes incubation was followed by
erythrocyte lysing according to manufacturers instructions (BD
FACS Lysing Solution [BD Biosciences, Heidelberg, Germany]).
By adding of PBS/1% FBS samples were washed twice (1250 rpm,
5 minutes, room temperature [RT]). Finally, the pellet was
resuspended with 200 ml of PBS/3% formaldehyde (Merck,
Darmstadt, Germany). Data were acquired on a BD FACSCan-
toIITM Flow Cytometer and analysed using the BD FACSDI-
VATM software (both BD Biosciences, Heidelberg, Germany).
Cell Transplantation
The NA-BMCs transferred from one dish into a new dish for 3
days and non adherent cells were harvested at day four, washed in
PBS and pelleted. After that, 3 wash steps with normal saline
(0.9% NaCl) followed. Murine splenocytes were used freshly after
preparation. Finally, the cell concentration was adjusted to
26106–16107 cells per 150 ml of sterile 0.9% NaCl. For co-
transplantation experiments, 46106 of allogeneic murine spleno-
cytes were added to 16107 of allogeneic bone marrow cells. The
grafts were subsequently injected intravenously within the next 7
hours into the lateral tail vein of lethally irradiated recipient mice.
Engraftment of cells was investigated for 50 days.
Statistical Analysis
All data are presented as means6SD. Non-linear regression
models for describing the time course of hematological parameters
as a function of dose and time were developed by Mr. Thomas
Keller, PhD (ACOMED statistics, Leipzig, Germany) by using
SPSS 15.0 software package (SPSS Science, Erkrath, Germany,
supplementary material 1). Statistic analysis and graphic presen-
tation were made using SigmaPlot 10.0/SigmaStat 3.5 software
(SYSTAT, Erkrath, Germany).
Supporting Information
Figure S1 Development of non-linear regression models of
function parameter = function (dose, time) for red blood cell count
(RBC) and determination of the lethal irradiation dose. (A) Time
was modeled using exponential decay and sigmoidal increase or
decay. Both functions are related to typical damage processes and
growth processes, respectively. (B) Groups of four mice were
irradiated with X-Rays (0 Gy, 3 Gy, 6 Gy, 8 Gy, 12 Gy). Survival
for doses $8 Gy is significantly shorter than for doses ,8 Gy.
Found at: doi:10.1371/journal.pone.0006157.s001 (0.04 MB
PDF)
Figure S2 Complete comparative flow cytometric analysis of
bone marrow and NA-BMCs from Balb/c and C57Bl/6. Cells
were gated for CD45 expression and co-expression of CD4, CD8,
CD19, CD117, CD117+/CD90low, CD31, CD11b, MHC-II,
CD90 for bone marrow cells and NA-BMCs derived from Balb/c
and C57Bl/6.
Found at: doi:10.1371/journal.pone.0006157.s002 (0.01 MB
PDF)
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